Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

By H. Scher, S. Halabi, I. Tannock, M. Morris, C. Sternberg, M. Carducci, M. Eisenberger, Celestia S. Higano, G. Bubley, R. Dreicer and 10 more. Journal of Clinical Oncology, 2008

2,212 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/702a10013255378ba8463bda8395026cc99cb89d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Celestia S. Higano
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. Steven Joniau
6. Thomas Wiegel
7. M. Hallek

Citations in the corpus

• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “The Prostate Cancer Clinical Trials Working Group (PCWG2) clarified the definition of bone scan progression, at least for patients enrolled in clinical trials, as the appearance of at least two new lesions [64] that are later confirmed.”
• ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer (2019, methodology): “Radiographic progression was documented by central review according to Prostate Cancer Working Group 2 criteria for bone assessment.(25) All deaths (in the absence of evidence of radiographic progression), regardless of timing, were included.”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “The Prostate Cancer Clinical Trials Working Group (PCWG2) clarified the definition of bone scan progression, at least for patients enrolled in clinical trials, as the appearance of at least two new lesions [89] that are later confirmed.”
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. (2018, neutral): “789 Enzalutamide 20 (10) 4 (15) 12 (9) 3 (7) Both abiraterone and enzalutamide 46 (23) 6 (22) 27 (20) 13 (31) Neither abiraterone nor enzalutamide 55 (27) 7 (26) 42 (32) 8 (19) Interval between mCRPC and baseline biopsy on study, months 17.”